atrasentan has been researched along with lu 208075 in 1 studies
| Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) | Studies (lu 208075) | Trials (lu 208075) | Recent Studies (post-2010) (lu 208075) |
|---|---|---|---|---|---|
| 358 | 41 | 108 | 298 | 54 | 227 |
| Protein | Taxonomy | atrasentan (IC50) | lu 208075 (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.195 | |
| Endothelin receptor type B | Homo sapiens (human) | 0.6925 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0114 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chapman, M; Kohan, DE; Rees, S; Stuart, D; Woodward, S | 1 |
1 other study(ies) available for atrasentan and lu 208075
| Article | Year |
|---|---|
Myocardial, smooth muscle, nephron, and collecting duct gene targeting reveals the organ sites of endothelin A receptor antagonist fluid retention.
Topics: Animals; Atrasentan; Body Fluids; Edema; Endothelin A Receptor Antagonists; Kidney Tubules, Collecting; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Myocardium; Nephrons; Organ Specificity; Phenylpropionates; Pyridazines; Pyrrolidines; Receptor, Endothelin A; Sodium Chloride, Dietary; Species Specificity | 2013 |